Literature DB >> 9395149

Reasons for substance use in schizophrenia.

J Addington1, V Duchak.   

Abstract

Abuse of and dependence on drugs, alcohol and other substances in schizophrenia are being increasingly recognized and well documented in the literature. It has been suggested that up to 60% of patients with schizophrenia use illicit drugs. A total of 41 subjects who fulfilled DSM-III-R criteria for schizophrenia and substance abuse or dependence were asked to describe their reasons for using such substances, the reasons why they might stop and the subjective effects of the substances. Drugs were reportedly used to increase pleasure, to 'get high' and to reduce depression. However, subjective effects of increased depression and positive symptoms were also reported. These results are considered in the context of potential treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395149     DOI: 10.1111/j.1600-0447.1997.tb09925.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  27 in total

1.  Perceived reasons for substance misuse among persons with a psychiatric disorder.

Authors:  Alexandra B Laudet; Stephen Magura; Howard S Vogel; Edward L Knight
Journal:  Am J Orthopsychiatry       Date:  2004-07

2.  Genetic predisposition to schizophrenia associated with increased use of cannabis.

Authors:  R A Power; K J H Verweij; M Zuhair; G W Montgomery; A K Henders; A C Heath; P A F Madden; S E Medland; N R Wray; N G Martin
Journal:  Mol Psychiatry       Date:  2014-06-24       Impact factor: 15.992

3.  A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.

Authors:  Taiwo Babatope; Jigar Chotalia; Rania Elkhatib; Satyajit Mohite; Joel Shah; Sumana Goddu; Ruchir Arvind Patel; Osarhiemen Ruth Aimienwanu; Devanshu Patel; Titilayo Makanjuola; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2016-12

Review 4.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

Review 5.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

6.  Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia.

Authors:  Anna Buadze; Rudolf Stohler; Beate Schulze; Michael Schaub; Michael Liebrenz
Journal:  Harm Reduct J       Date:  2010-09-28

7.  Application of the Transtheoretical Model of change: psychometric properties of leading measures in patients with co-occurring drug abuse and severe mental illness.

Authors:  Melissa Nidecker; Carlo C DiClemente; Melanie E Bennett; Alan S Bellack
Journal:  Addict Behav       Date:  2008-04-08       Impact factor: 3.913

8.  Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure.

Authors:  Ruth Salo; Catherine Fassbender; Ana-Maria Iosif; Stefan Ursu; Martin H Leamon; Cameron Carter
Journal:  Psychiatry Res       Date:  2013-07-26       Impact factor: 3.222

9.  Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis.

Authors:  Danielle A Schlosser; Rahel Pearson; Veronica B Perez; Rachel L Loewy
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2012-04

10.  European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods.

Authors:  Prisca Weiser; Thomas Becker; Carolin Losert; Köksal Alptekin; Loretta Berti; Lorenzo Burti; Alexandra Burton; Mojca Dernovsek; Eva Dragomirecka; Marion Freidl; Fabian Friedrich; Aneta Genova; Arunas Germanavicius; Ulaş Halis; John Henderson; Peter Hjorth; Taavi Lai; Jens Ivar Larsen; Katarzyna Lech; Ramona Lucas; Roxana Marginean; David McDaid; Maya Mladenova; Povl Munk-Jørgensen; Alexandru Paziuc; Petronela Paziuc; Stefan Priebe; Katarzyna Prot-Klinger; Johannes Wancata; Reinhold Kilian
Journal:  BMC Public Health       Date:  2009-08-28       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.